Researchers at Karolinska Institutet have successfully delivered targeted cancer treatment via small membrane bubbles our cells use to communicate. A new study published in Nature Biomedical Engineering shows that the treatment reduces tumour growth and improves survival in mice.
When our cells communicate, they send out small membrane bubbles known as extracellular vesicles which contain various signalling molecules. Interest in these tiny bubbles, sometimes called the body’s ‘message in a bottle’, has increased recently as they could be used to deliver medicines.
Blood samples in test tubes. Image credit: NCI
Antibodies seek out tumours
Researchers at Karolinska Institutet have now created a targeted cancer treatment by loading these bubbles with a chemotherapeutic drug and attaching antibodies against tumours to their surface. In addition to targeting tumour cells, the antibodies act as a form of immunotherapy, resulting in an enhanced therapeutic effect. The treatment reduced tumour growth and improved survival when given as an injection to mice with breast cancer or melanoma.
“By attaching different antibodies to extracellular vesicles, we can target them to virtually any tissue and we can load them with other types of drugs as well,” says Oscar Wiklander, physician and researcher at the Department of Laboratory Medicine, Karolinska Institutet, and joint first author with Doste Mamand, researcher at the same department. “Therefore, the treatment has the potential to be used against other diseases and cancer types.”
More effective and fewer side effects
The hope is that the new treatment will be more specific and effective in eliminating tumour cells without affecting healthy tissue, compared to current treatment strategies. The researchers plan to investigate whether different combinations of antibodies and drugs can further improve treatment.
“Among other things, we want to investigate the possibility of delivering mRNA as an anticancer drug,” says the study’s last author Samir EL Andaloussi, Professor at the Department of Laboratory Medicine, Karolinska Institutet. “Ultimately, we hope this can lead to a new treatment platform that can improve treatment efficacy and reduce side effects in difficult-to-treat diseases, especially cancer.”
Source: Karolinska Institutet